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Background: Many studies have examined specific mutations in 
patients with resected lung adenocarcinoma across heterogeneous 
stages, comprising predominantly advanced/metastatic disease, but 
there is little data regarding the mutation profile of patients with early 
stage node negative disease. The aim of this study was to identify pat-
terns of mutations in early stage node negative lung adenocarcinoma.
Methods: A total of 204 patients who underwent resection for stage 
IB (sixth Ed American Joint Committee on Cancer) lung adenocar-
cinoma and received no neoadjuvant or adjuvant treatments were 
identified. Tumors were genotyped using the OncoCarta v1.0 kit 
(Sequenom, San Diego, CA) on the Sequenom MassARRAY plat-
form. Fluorescence in situ hybridization for ALK rearrangement was 
also performed.
Results: A total of 110 (54%) patients’ tumors harbored at least one 
mutation. KRAS, EGFR, PIK3CA, ALK, PDGFRA, AKT1, BRAF, 
FGFR1, and HRAS mutations were detected in tumors from 77 
(37.7%), 29 (14.2%), 9 (4.4%), 2 (1%), 2 (1%), 1 (0.5%), 1 (0.5%), 
1 (0.5%), and 1 (0.5%) patients respectively. Synchronous mutations 
(either comutations or double mutations) were identified in 18 (8.8%) 
patients. KRAS and PIK3CA mutations were associated with poorly 
differentiated tumors (p = 0.03; p = 0.02), whereas EGFR mutations 
were associated with well-differentiated tumors (p = 0.001). Five 
tumours contained EGFR mutations (one T790M and four exon 20 
insertions), which are associated with resistance to EGFR tyrosine 
kinase inhibitors (EGFR-TKIs).
Conclusions: Diverse patterns of mutations are seen in resected 
node-negative lung adenocarcinoma including an unexpectedly low 
rate of ALK rearrangement, EGFR mutations associated with resis-
tance to EGFR-TKIs and a high rate of synchronous mutations. 
These data may influence the design of future adjuvant targeted 
therapy trials.
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(J Thorac Oncol. 2013;8: 408-414)
Lung cancer is the second most common cancer and the leading cause of cancer death worldwide, with an incidence 
of 1.6 million new cases annually and a mortality of 1.38 million 
in 2008.1 For the past two decades, decisions regarding lung 
cancer treatment have been based largely on the histological 
distinction between non–small-cell (NSCLC) and small-cell 
lung carcinoma. In recent years, more definitive histological 
classifications and identification of somatic mutations have 
become an essential component in determining the management 
of NSCLC. Molecular driven therapeutic targets such as 
epidermal growth factor receptor gene (EGFR)2 and abnormal 
fusion of echinoderm microtubule-associated protein-like 4 
and anaplastic lymphoma kinase genes (EML4-ALK)3 have 
resulted in a paradigm shift in the treatment of advanced lung 
adenocarcinoma. However, in early NSCLC, surgical resection 
remains the treatment of choice with adjuvant chemotherapy 
having a modest absolute survival benefit of 5% at 5 years in 
stage II–IIIA disease, but an equivocal effect only in stage IB 
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disease.4 Several studies have assessed the presence of specific 
mutations, predominantly KRAS, EGFR, and PIK3CA,5–7 
in patients with resected lung adenocarcinoma across a 
heterogeneous group of stages, but there is little data on the 
mutation profile of patients with early stage disease. Inevitably, 
the design of future adjuvant trials of targeted therapies in early 
stage lung adenocarcinoma will be based on the mutation data 
from advanced/metastatic disease. Therefore, our aim was to 
examine a mutation profile in a cohort of patients who had 
resected early node-negative lung adenocarcinoma to inform 
better the design of future clinical trials.
PATIENTS AND METHODS
We retrospectively reviewed 204 patients with stage IB 
primary lung adenocarcinoma according to the American Joint 
Commission on Cancer, (AJCC) sixth edition tumor-node-
metastasis (TNM) staging system,8 who underwent surgical 
resection between January 1990 and May 2008. Patients who 
received neoadjuvant or adjuvant treatments were excluded. 
Pathology reports were reviewed and pathologic characteris-
tics (tumor size, histopathologic type, grade, visceral pleural, 
vessel, and perineural invasion) were extracted. Two represen-
tative formalin fixed paraffin embedded (FFPE) tumor blocks 
from each case were retrieved from the anatomical and tis-
sue pathology archives. They were sectioned and stained with 
hematoxylin and eosin. An experienced pulmonary pathologist 
(W.A.C.) reviewed the slides and marked representative areas. 
Two 1-mm cores of the marked representative areas from 
FFPE tissue were collected for DNA extraction. This study was 
approved by the Human Research Ethics Committee of Royal 
Prince Alfred Hospital. (X10-0278; HREC/10/RPAH/491)
Mutation Detection
DNA was extracted from the FFPE tissue using 
NucleoSpin FFPE DNA Kit (Macherey Nagel, Düren, 
Germany) according to the manufacturer’s instruction with 
an overnight proteinase digestion. The quality and quantity of 
the extracted DNA was assessed using NanoDrop ND-1000 
Spectrophotometer (NanoDrop Technologies, Wilmington, 
DE). A minimum of 480 ng of DNA was required for success-
ful mutational analysis. Samples were amplified for 238 vari-
ant targets in a 24-multiplex PCRs using the OncoCarta Panel 
v1.0 Kit (ABL1, AKT1, AKT2, BRAF, CDK, EGFR, ERBB2, 
FGFR1, FGFR3, FLT3, JAK2, KIT, MET, HRAS, KRAS, 
NRAS, PDGFR, PIK3CA, and RET) and analyzed based on the 
matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF) technology on the Sequenom 
MassArray platform.9,10 The targeted mutations in the 19 
oncogenes comprising the OncoCarta v1.0 Panel are reported 
to be biologically significant in carcinogenesis or progres-
sion in a range of malignancies. These mutational analyses 
and Fluorescence in situ hybridization (FISH) for ALK rear-
rangement described below were performed at an Australian 
National Association of Testing Authorities (NATA) accred-
ited laboratory to the ISO15189 standard, which is compa-
rable to the Clinical Laboratory Improvement Amendments 
(CLIA) in the United States. NATA accreditation provides a 
mechanism to determine, formally recognize and promote the 
competence of facilities in performing specific types of test-
ing. It also ensures that the accredited laboratory operates at 
a high standard with internal and external quality assurance 
measures.
FISH for ALK Rearrangement
Interphase fluorescence in situ hybridisation for 
ALK rearrangement was performed on tissue microarrays 
 constructed from all cases for ALK rearrangement using the 
Vysis LSI ALK Dual Color, Break Apart Rearrangement 
Probe (Abbott Molecular, Abbott Park, IL). This probe detects 
rearrangements in chromosome 2p23 encompassing the ALK 
gene, which includes a SpectrumOrange labeled 250 kb DNA 
fragment telomeric to ALK (3′ end) and a SpectrumGreen 
labeled 300 kb DNA fragment centromeric to ALK (5′ end). 
The probe set does not identify the specific rearrangement 
gene partner. Tissue microarray tissue sections of 4 μm were 
baked at 60 oC overnight and stained for ALK FISH accord-
ing to the manufacturers instructions, except that Invitrogen 
Pretreatment Solution (Life Technologies, Grand Island, NY) 
was used at 98–102 oC for 20 minutes.
Signals were counted in at least 100 tumor nuclei per 
case using an epifluorescence microscope (Zeiss , Oberkochen, 
Germany). FISH for ALK locus rearrangement was consid-
ered positive if at least 15% of cells analyzed showed either 
a split of one set of red and green signals greater than one 
signal width apart, and/or if loss of one green signal had 
occurred.3,11–14
A positive control consisting of an independently 
 validated lung tumor confirmed by FISH to be positive for 
ALK rearrangement was included. Negative controls included 
an independently validated lung tumor confirmed by FISH to 
be negative for rearrangement and normal lung tissue.
Statistical Analysis
Visceral pleural invasion was consistently reported, 
but more than 50% of cases had missing data for vessel and 
perineural invasion. Therefore, vessel and perineural invasion 
were not included in the subsequent analysis.
To examine the relationship between categorical 
 variables, Pearson χ2 test with continuity correction and 
Fisher’s exact test were performed where appropriate. Linear-
by-linear association χ2 test was used to evaluate trend for 
ordinal variable. All p values were two-sided and a p value 
less than 0.05 was considered significant. Kaplan–Meier anal-
ysis was used to determine the overall survival and differences 
between genotypes were compared using the log-rank test. All 
statistical analyses were performed using PASW Statistics 
version18.0 (SPSS Inc., Chicago, IL).
Terminology
DNA variants refer to any DNA change while mutations 
imply pathogenicity. Double mutation refers to synchronous 
mutations within a single oncogene while comutation refers to 
synchronous mutations within two different oncogenes.
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RESULTS
The clinical characteristics of 204 patients with resected 
node-negative primary lung adenocarcinoma are described in 
Table 1. The majority of patients (80.4%) underwent lobec-
tomy because of the early stage of the disease.
There were 110 (54%) patients whose tumors harbored 
at least one mutation with 18 patients having two or more 
mutations (Fig. 1A). KRAS, EGFR, PIK3CA, MET variants, 
and PDGFRA mutations/variants were detected in tumors 
from 77 (37.7%), 29 (14.2%), 9 (4.4%), 7 (3.4%), and 2 
(1%) patients respectively (Table 2). AKT1, BRAF, FGFR1, 
and HRAS mutations were uncommon, and all except for the 
BRAF mutation coexisted with another oncogene mutation 
(Table 2; Fig. 1B). There were only two patients whose tumors 
had ALK rearrangement. The median survival was 6.5 years 
and 5-year survival rate was 55%. There was a trend to sug-
gest that patients whose tumors harbored KRAS (p = 0.055) 
and PIK3CA (p = 0.046) mutations had a poor prognosis but 
such trend was not observed in those with EGFR mutations (p 
= 0.5). (Fig. 2A–C)
The relationship between clinicopathologic factors and 
mutation patterns were assessed. EGFR mutations were more 
common in women than men (23.8% versus 7.5%). However, 
no sex difference was observed in tumors with KRAS and 
PIK3CA mutations. Tumors containing KRAS mutations were 
more likely to be poorly differentiated (p = 0.03) as were tumors 
containing PIK3CA mutations (p = 0.02). Conversely, EGFR 
mutations were associated with well-differentiated tumors (p = 
0.001). There were no associations between mutation patterns 
and visceral pleural invasion or tumor size (p > 0.05).
KRAS
The most common mutation identified was in the KRAS 
gene. All KRAS mutations were missense changes and were 
identified at codons 12, 13, or 61. The mutations were mutually 
exclusive from EGFR mutations (p < 0.001). Ten patients who 
had KRAS-mutant tumors had comutations; five (6.5%) had 
PIK3CA mutations, three (3.9%) had MET variants, one had a 
PDGFRA mutation, and one had an AKT1 mutation (Table 2).
EGFR
The second most common mutation identified was 
in the EGFR gene (Table 2). Of the 29 patients with EGFR 
 mutations, 12 (43%) of tumors harbored common classic 
mutations in exon 19 (in-frame simple deletions) and only 7 
(24%) contained the L858R mutation in exon 21, whereas 14% 
of EGFR mutations were seen in exon 18. Unexpectedly, five 
tumors contained EGFR mutations associated with resistance 
to epidermal growth factor receptor tyrosine kinase inhibitors 
(EGFR-TKIs) therapy. One patient had a tumor with a T790M 
mutation and four had tumors containing exon 20 insertions. 
Furthermore, two patients had comutations with other onco-
genes (PIK3CA and FGFR1) in addition to EGFR mutations 
(Table 2). There were four patients whose tumors harbored 
double EGFR mutations, two different EGFR mutations 
(one G719C + E709A, one G719A + S768I, and two G719S + 
S768I) found simultaneously in a single tumor (Table 2).
PIK3CA
Only nine of the 204 patients had mutations in the 
PIK3CA gene. Mutations were not only detected at the hotspot 
locations of exon 9 (helical domain) and exon 20 (kinase 
TABLE 1.  Clinicopathologic Characteristics of 204 Patients 
with Resected Stage IB Lung Adenocarcinoma
Clinicopathologic factors (N = 204) Number (%)
Median age 69 (range 40–87)
Gender
 Male 120 (59)
 Female 84 (41)
Type of operation
 Lobectomy 164 (80)
 Pneumonectomy 13 (7)
 Wedge resections/segmentectomy 27 (13)
Tumor size
 Less than or equal to 5 cm 155 (76)
 5.1 to 7 cm 30 (15)
 Greater than 7 cm 18 (9)
 Unknown 1
Histopathological grade
 Well differentiated 26 (13)
 Moderately differentiated 116 (56)
 Poorly differentiated 62 (30)
Visceral pleural invasion
 Yes 85 (42)
 No 103 (50)
 Not reported 16 (8)
FIGURE 1. (A) Distribution of number of mutations/variants 
present. (B) Frequency of different mutations/variants and 
ALK rearrangement.
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domain), but also two cases had an R38H mutation, which was 
located at the p85 binding domain away from the helical and 
kinase domains. Of the nine patients, seven had comutations 
with another oncogenes predominantly KRAS, although 
there was one case of a PIK3CA mutation coexisting with an 
EGFR (L858R) mutation. There was also one case in which 
two PIK3CA mutations (E545K + M1043I) were identified 
coexisting with a HRAS mutation. (Table 2)
MET
Like PIK3CA mutations, MET variants were relatively 
uncommon (Table 2). The majority of MET variants were the 
T992I, whereas one tumor contained a R970C variant. These 
variants are located within the coding region for the juxta-
membrane domain. Further analysis demonstrated that the 
MET variants were also present in the matched non-neoplastic 
lung tissue, indicating that these were germline variants rather 
than somatic mutations.
DISCUSSION
This study demonstrates that mutations are common 
in resected early node-negative, treatment-naive lung 
adenocarcinoma with 54% of patients having tumors which 
harbor at least one biologically relevant mutation. Although 
mutations in KRAS, EGFR and ALK were mutually exclusive, 
some tumors harbored synchronous mutations within a single 
oncogene such as double EGFR mutations or within two different 
oncogenes in the case of comutations. Unexpectedly, there were 
also mutations associated with drug resistance despite the fact 
that this was a cohort of early stage disease patients who had not 
been treated with chemotherapy or targeted agents.
The baseline characteristics of our cohort are similar to 
other reported studies, which have sought to identify patterns 
of gene mutations in NSCLC.5–7 Most of these studies have 
analyzed the pattern of specific somatic mutations (EGFR 
and KRAS or PIK3CA) in cohorts of adenocarcinoma with 
heterogeneous disease stage including locally advanced/met-
astatic disease and patients who had been exposed to various 
treatments.5–7 In contrast, we performed a wider mutational 
analysis encompassing EGFR, KRAS, PIK3CA, and ALK, 
PDGFRA, FGFR1, AKT1 and HRAS. In addition, the cohort 
in this study was homogeneous in stage (node negative adeno-
carcinoma) and treatment (surgery only). Our rate of EGFR, 
KRAS, and PIK3CA mutations was comparable to published 
cohorts of NSCLC in western population,2,7,15–18 but our rate of 
ALK rearrangement (1%) was lower than generally reported 
in advanced NSCLC (5%).3 Furthermore, we identified a 
higher rate of multiple mutations than previously reported in 
other studies.19,20 This is of considerable importance as pre-
clinical and clinical studies demonstrate that tumors with 
comutations may have different responses to targeted therapy 
depending on the combinations of oncogenes.21–23 Although 
we interrogated a more extensive set of mutations in a larger 
range of oncogenes than other studies, the panel still has its 
TABLE 2.  DNA Mutations and Variants identified in 204 Patients with Resected Stage IB Adenocarcinoma
KRAS mutation 
N = 77 (37.7%)
EGFR mutation 
N = 29 (14.2%)
PIK3CA mutation 
N = 9 (4.4%)
MET variant 
N = 7 (3.4%)
Gender
 Male 47 (61%) 9 (31%) 6 (67%) 5 (71%)
 Female 30 (39%) 20 (69%) 3 (33%) 2 (29%)
Mutation Subtypes Exon 2 (92%) Exon 18 (14%) Exon 9 (56%) R970C 1 (14%)
G12A 3 G719A 1 E545K 5 T992I 6 (86%)
G12C 26 G719S 2
G12D 13 G719C + E709A 1 Exon 20 (11%)
G12R 2 H1047R 1
G12S 1 Exon 19 (43%)
G12V 23 Deletions 12 Others (33%)
G13D 3 R38H 2
Exon 20 (29%) E545K + M1043I 1
Exon 3 (8%) T790M 1
Q61H 6 Insertions 4
S768I 3
Exon 21 (29%)
L858R 7
L861Q 1
Comutations PIK3CA 5 PIK3CA 1 KRAS 5 KRAS 3
MET 3 FGFR1 1 HRAS 1
PDGFRA 1 EGFR 1
AKT1 1
Double mutations in a single oncogene 0 4 1 0
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limitations. Naturally, there are potentially other significant 
oncogenic mutations which may be found on more detailed 
sequencing.
In a western population, approximately 20% of lung 
adenocarcinomas contain EGFR mutations. The common-
est classic EGFR mutations at exon 19 (in-frame deletions) 
and exon 21 (missense mutation L858R) together account 
for approximately 90% of EGFR mutant tumors in published 
studies.24,25 However, they are less prevalent, accounting for 
only 66% of EGFR mutations in our cohort. On the other 
hand, EGFR mutations associated with EGFR-TKIs resis-
tance were identified, including the T790M mutation and exon 
20 insertions. In particular, EGFR exon 20 insertion muta-
tions were more common in our study (14%) than reported 
by Yasuda et al.26 (5%). This could be explained by the use 
of the more sensitive multiplexed system array technology as 
Su et al.27 demonstrated that the MALDI-TOF method is as 
sensitive as next generation sequencing, and more sensitive 
than Sanger sequencing. Furthermore, one of the four double 
EGFR mutation combinations identified in our study, G719C 
FIGURE 2.  Kaplan–Meier overall survival curves of KRAS, EGFR, and PIK3CA wild-type and mutant populations censored at 10 years.
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+ E709A has been associated with EGFR-TKI resistance.28 
An in vitro study demonstrated that the combination of 
G719C and E709A EGFR mutations attenuated the response 
to gefitinib as compared with the individual mutations alone.28 
The rest of the tumors, which contained double EGFR muta-
tions (G719A/S + S768I), were the combination of a sensitive 
mutation and a resistant mutation to EGFR-TKIs. It is unclear 
how these mutation patterns will affect the response to EGFR-
TKIs. Therefore, it is important to examine the entire EGFR 
kinase domain from exon 18 to 21 for EGFR mutations and 
their specific subtypes to avoid missing nonclassic yet clini-
cally relevant EGFR mutations.
Mutations in the KRAS oncogene are the most common 
somatic mutation in lung adenocarcinoma. Meta-analysis29 
suggests that KRAS mutant cancers have a poorer prognosis 
regarding overall survival and a poor response to EGFR-TKIs. 
However, these data are contradictory and independent valida-
tion studies have failed to produce a consensus view. There 
is increasing evidence that the subtype of KRAS mutations 
may be important with KRAS codon 13 mutations (G13D) 
predicting for significantly poorer survival with adjuvant che-
motherapy in the four large clinical trials of adjuvant chemo-
therapy in early NSCLC.30 More recently, a phase II study has 
demonstrated that selumetinib, a MEK inhibitor, combined 
with docetaxel improves overall survival, response rate and 
progression-free survival in patients with advanced NSCLC 
whose tumor harbored KRAS mutations.31
In our cohort, PIK3CA comutations were much more 
common than isolated PIK3CA mutations suggesting these 
mutations may modulate tumor biology in concert with 
other genetic mutations rather than being the primary driver. 
Halilovic et al.32 speculated that comutations provide a fail-safe 
mechanism for cancer cells to grow and proliferate when facing 
environmental stress such as hypoxia. Our study demonstrated 
a 78% rate of PIK3CA mutations coexisting with mutations in 
other genes, almost all being RAS mutations, upstream from 
the PIK3CA signaling cascade. Little is known about the clini-
cal implications of PIK3CA mutations in NSCLC, although 
data from other cancer types have suggested that PIK3CA 
mutations may predict for a poor prognosis in breast cancer 
and are associated with resistance to cetuximab in colorectal 
cancer. It is unclear what functional implication these comuta-
tions may have on response to potential treatments.
MET is a proto-oncogene located at chromosome 7 
(7q31) and has been implicated in metastases and invasion in 
a variety of cancers.33 Although MET nonsynonymous vari-
ants (R970C and T992I) in NSCLC are reported to be germ-
line variants without transforming ability, they may still play 
a role in tumorgenesis particularly when combined with an 
oncogene that drives cellular proliferation such as KRAS.34,35 
Germline variants can influence tumor biology, for instance an 
FGFR4 germline variant Arg388 is associated with resistance 
to adjuvant therapy in primary breast cancer.36 The biological 
significance of germline MET variants remains to be seen.
We found a trend towards poor prognosis among 
patients whose tumors contained KRAS or PIK3CA mutations 
but not in those with EGFR mutations. However, the num-
ber of patients examined within these subgroups was small. 
Therefore, the prognostic value of presence of specific muta-
tions remains to be validated in larger studies.
In summary, we have demonstrated diverse patterns 
of mutations in resected early stage, node negative lung 
adenocarcinoma which can be used to inform future clinical 
research. For example, the low rate of ALK rearrangement 
suggests that adjuvant trials with crizotinib are unlikely to 
be successful. Furthermore, the presence of EGFR mutations 
associated with resistance to EGFR-TKIs may influence the 
results of adjuvant trials of erlotinib or gefitinib, whereas 
comutations associated with signaling pathways such as 
PIK3CA may also affect response to therapy. Our data provide 
compelling evidence for comprehensive tumor mutation 
profiling as an essential element of adjuvant trial design as 
DNA changes present in advanced cancer cohorts do not 
necessarily match those from early stage disease.
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